Evidence map›Paper›PMID 26048782›Full record

ArticleBioorganic & medicinal chemistry letters2015

(18)F-Fluorodeoxyglucamines: Reductive amination of hydrophilic (18)F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents.

Aparna Baranwal, Jogeshwar Mukherjee

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aparna BaranwalPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, United States.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, United States. Electronic address: j.mukherjee@uci.edu.
University of California, Irvine · US

Funding

PET Imaging Agents for Nicotinic a4b2 ReceptorsR01AG029479 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MUKHERJEE, JOGESHWAR · 2007 to 2017
$2.6M
PET Imaging agents for a4b2 Nicotinic ReceptorsRF1AG029479 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI CHRISTIAN, BRADLEY T, MUKHERJEE, JOGESHWAR · 2019 to 2020
$2.2M
NIA NIH HHS R01 AG029479NIA NIH HHS RF1 AG029479
6 · The paper itself

Abstract

Maillard reaction of (18)F-FDG with biological amines results in the formation of (18)F-fluorodeoxyglycosylamines ((18)F-FDGly) as pseudo-Amadori products. To increase in vivo stability, we report the reductive amination of FDGly to provide reduced fluorodeoxyglucamines (FDGlu). (18)F-Fluorodeoxyglucamines ((18)F-FDGlu), resulting from linking (18)F-FDG (hydrophilic) to lipophilic molecules containing amine group may be useful as positron emission tomography (PET) imaging agents. Two amine derivatives, 7-chloro-8-hydroxy-3-methyl-l-(3'-aminophenyl)-2,3,4,5-tetrahydro-lH-3-benzazepine (SCH 38548 for dopamine D1 receptors) and BTA-0 (for Aβ amyloid) were reacted with FDG under reductive amination conditions to yield stable products, FDGluSCH and FDGluBTA. FDGluSCH had high binding affinity to rat brain dopamine D1 receptors with a Ki of 19.5 nM while FDGluBTA had micromolar affinity for human frontal cortex Aβ plaques. (18)F-FDGluSCH was prepared in low to modest radiochemical yields and preliminary results showed binding to the rat striatum in brain slices. In vivo stability of(18)F-FDGluSCH needs to be determined. Our results suggest that (18)F-FDG is a useful 'radioactive synthon' for PET radiotracer development. Its usefulness will have to be determined on the basis of the structure-activity relationship of the target molecule.

Indexed as

Positron-Emission TomographyAminationAminesAnimalsBrainFluorodeoxyglucose F18HumansOxidation-ReductionRadiopharmaceuticalsRatsReceptors, Dopamine D1AminesFluorodeoxyglucose F18RadiopharmaceuticalsReceptors, Dopamine D1(18)F-FDG(18)F-FluorodeoxyglucamineDopamine D1 receptorImagingPET

Identifiers

PMID26048782
PMCPMC4469266
OpenAlexW828858932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.